Financial Insights

Barrington Remains a Buy on AMC Entertainment (AMC)

In a report released today, James Goss from Barrington maintained a Buy rating on AMC Entertainment (AMC). The company’s shares opened today at $16.50. According to TipRanks.com, Goss is a 5-star analyst with an average return of 16.3% and a 70.3% success rate. Goss covers the Services sector, focusing on stocks such as Lions Gate […]

3
Like
Save
Inogen (INGN) Gets a Buy Rating from Needham

In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen (INGN), with a price target of $191. The company’s shares opened today at $92.30, close to its 52-week low of $88.21. According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.2% and a 66.8% success rate. […]

2
Like
Save
Cantor Fitzgerald Keeps a Buy Rating on Xencor Inc (XNCR)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Xencor Inc (XNCR) today and set a price target of $40. The company’s shares opened today at $32.50. Young commented: “. We reiterate our Overweight rating and $40 price target. We think Xencor’s collaboration and license agreement with Astellas (ALPMF, NC) marks another source of […]

5
Like
Save
Chinese Government Bonds: The Elephant in the Room

China’s government fixed-income market constitutes a US $12-trillion opportunity, according to Emil Nguy.

9
Like
Save
Will Tesla’s (TSLA) Tale of Two Guidances Weigh on Stock?

Among the most polarizing stocks on Wall Street is one of it’s most famous — Tesla (TSLA). Since the beginning of last year, shares have climbed or dropped at least 10% more than a dozen times, as some in the investment community look at the stock as a can’t-lose, with others thinking there’s no chance the […]

8
Like
Save
Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27. McCarthy commented: “Following last month’s clearance to begin its European clinical trial of WP1220 (STAT3 inhibitor) in the topical treatment of cutaneous T-cell lymphoma […]

4
Like
Save
13 Charts: High Yield Today

The standard joke about high-yield bonds is that they’re not high yield any longer. Let’s replace it with something better.

6
Like
Save
Jones Lang Lasalle Inc (JLL) Gets a Buy Rating from Barclays

Barclays analyst Ross L Smotrich maintained a Buy rating on Jones Lang Lasalle Inc (JLL) yesterday and set a price target of $184. The company’s shares closed yesterday at $165.60. According to TipRanks.com, Smotrich is a 5-star analyst with an average return of 7.2% and a 67.9% success rate. Smotrich covers the Financial sector, focusing […]

9
Like
Save
Book Review: Keeping Your Dividend Edge

In Keeping Your Dividend Edge, Todd Wenning, CFA, describes the new market environment that necessitates a revised approach for selecting and monitoring dividend-paying stocks.

5
Like
Save
Meritage Corp (MTH) Gets a Hold Rating from Wedbush

Wedbush analyst Jay McCanless maintained a Hold rating on Meritage Corp (MTH) today and set a price target of $39. The company’s shares closed yesterday at $44.70, close to its 52-week high of $44.83. According to TipRanks.com, McCanless is a 3-star analyst with an average return of 2.4% and a 47.8% success rate. McCanless covers […]

6
Like
Save